Evaluating antipsychotic medications: Predictors of clinical effectiveness: Report of an expert review panel on efficacy and effectiveness

Canadian Journal of Psychiatry

Volumn 48, Issue 3 SUPPL. 1, 2003, Pages

  Lalonde, Pierre ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGRANULOCYTOSIS; CARDIOMYOPATHY; CARDIOTOXICITY; DROWSINESS; DRUG CHOICE; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERPROLACTINEMIA; MITRAL VALVE REGURGITATION; MYOCARDITIS; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PERICARDIAL EFFUSION; PERICARDITIS; PRESCRIPTION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 0038242033     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Dorland's Illustrated Medical Dictionary. 28th ed. Philadelphia (PA): WB Saunders Company; 1994.
2. Committee for Evaluating Medical Technologies in Clinical Use, Division of Health Sciences Policy, Division of Health Promotion and Disease Prevention. Assessing medical technologies. Washington (DC): National Academy Press; 1985; p 71.
3. Summerfelt WT, Meltzer HY. Efficacy vs effectiveness in psychiatric research. Psychiatr Serv 1998;49:834-5.
4. Novartis Pharmaceuticals. Clozaril product monograph. Dorval (QC): Novartis Pharmaceuticals; 2002.
5. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-9.
6. Brar JS, Chengappa KN, Parepally H, Sandman AR, Kreinbrook SB, Sheth SA, Ganguli R. The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. Ann Clin Psychiatry 1997;9:227-34.
7. Avnon M, Rabinowitz J. Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. Br J Psychiatry 1995; 167:760-4.
8. Buckman RW, Malan RD. Clozapine for refractory schizophrenia: the Illinois experience. Clin Psychiatry 1999;60(Suppl 1):18-22.
9. Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998;43(Suppl 2):25S-40S.
10. Perry PJ, Bever KA, Arndt S, Combs MD. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998;44:733-8.
11. Hummel B, Dittmann S, Forsthoff A, Matzner N, Amann B, Grunze H. Clozapine as add-on medication in the maintenance treatment of bipolar and schizoaffective disorders. A case series. Neuropsychobiology 2002;45(Suppl 1):37-42.
12. Health Canada. Association of CLOZARIL (clozapine) with cardiovascular toxicity [letter]. Ottawa (ON): Health Canada; January 14, 2002.
13. Bustillo JR, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996;153:817-9.
14. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
15. Larach VW, Zamboni RT, Mancini HR, Mancini RR, Gallardo RT. New strategies for old problems: tardive dyskinesia (TD). Review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up. Schizophr Res 1997;28:231-46.
16. Oberholzer AF, Hendriksen C, Monsch AU, Heierli B, Stahelin HB. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992;4:187-95.
17. Pitner JK, Mintzer JE, Pennypacker LC, Jackson CW. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995;56:180-5.
18. Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull 2001;27:227-34.
19. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-55.
20. Janssen-Ortho Pharmaceuticals. Risperdal product monograph. Toronto (ON): Janssen-Ortho Pharmaceuticals; 2002.
21. Malla AK, Norman RM, Scholten DJ, Zirul S, Kotteda V. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry 2001;62:179-84.
22. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998;155:499-504.
23. Quintana H, Keshavan M. Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1995;34:1292-6.
24. Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999;60:658-63.
25. Vieta E, Goikolea JM, Corbella B, Benabare A, Reinares M, Martinez G, and others. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001;62:818-25.
26. McIntyre R, Mancini DA, McCann SM, Srinavasan J, Kennedy SH. Antidepresant efficacy and tolerability in bipolar disorder. [Poster P.2.E.066]. Poster presented at the 23rd Congress of the Collegium Internationale NeuroPsychopharmacologicum; 23-27 June 2002; Montreal, (QC).
27. Ellingrod VL, Schultz SK, Ekstam-Smith K, Kutscher E, Turvey, C, Arndt S. Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy 2002;22(1):1-5.
28. Belzie LR. Risperidone for AIDS-associated dementia: a case series. AIDS Patient Care STDS 1996;10:246-9.
29. Negron AE, Reichman WE. Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms. Int Psychogeriatr 2000;12:527-36.
30. Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001;62:282-9.
31. Owens DG. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55(Suppl):29-35.
32. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gall, G, and others. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002;41(3):337-43.
33. Haddad PM, Helleweil JS, Wieck A. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol 2001;15:293-5.
34. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002;3:1381-91.
35. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;28(Suppl 1):53-67.
36. Raja M. Risperidone-induced absence of ejaculation. Int Clin Psychopharmacol 1999;14:317-9.
37. Mahmoud R, Engelhart L, Ollendorf D, Oster G. The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. J Clin Psychiatry 1999;60(Suppl 3):42-7.
38. Lilly Pharmaceuticals. Zyprexa product monograph. Toronto (ON): Lilly Pharmaceuticals; 2002.
39. Dossenbach MR, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, Belmaker RH. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 2001;62(Suppl 2):28-34.
40. Littrell KH, Johnson CG, Hilligoss NM, Peabody CD, Littrell SH. Switching clozapine responders to olanzapine. J Clin Psychiatry 2000;61:912-5.
41. Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J Clin Psychiatry 1997;58:479-83.
42. Vieta E, Reinares M, Corbella B, Benabarre A, Gilaberte I, Colom F, and others. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol 2001;21:469-73.
43. Gonzalez-Pinto A, Lalaguna B, Mosquera F, Perez de Heredia JL, Gutierrez M, Ezcurra J, and others. Use of olanzapine in dysphoric mania. J Affect Disord 2001;66:247-53.
44. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, and others. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-9.
45. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63(12):1148-55.
46. Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, Beier A. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001;16(Suppl 1):S62-S70.
47. Mintzer J, Faison W, Street JS, Sutton VK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. Int J Geriatr Psychiatry 2001;16(Suppl 1):S71-S77.
48. Aarsland D, Larsen JP, Lim NG, Tandberg E. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999;11:392-4.
49. Walker Z, Grace J, Overshot R, Satarasinghe S, Swan A, Katona CL, McKeith IG. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999;14:459-66.
50. Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001;21:14-20.
51. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(Suppl 23):5-12.
52. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63(12):1135-9.
53. Gomez JC, Sacristan JA, Hernandez J, Breier A, Ruiz Carrasco P, Anton Saiz C, Fontova Carbonell E. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic study of olanzapine in schizophrenia. Clin Psychiatry 2000;61:335-43.
54. Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: a comparison ofolanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000;15:245-55.
55. AstraZeneca Pharmaceuticals. Seroquel product monograph. Mississauga (ON): AstraZeneca Pharmaceuticals; 2002.
56. Sharma T. Quetiapine-efficacy in different domains. Eur Neuropsychopharmacol 2001;11(Suppl 4):S385-S390.
57. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, Miller AL. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002;53:239-48.
58. Tauscher-Wisniewski S, Kapur S, Papatheodorou G, Jones C, Daskalakis ZJ, Zipursky B. Quetiapine in first-episode schizophrenia: treatment effects. International Congress on Schizophrenia Research; 2001; Whistler (BC). Abstract. p 247.
59. Tauscher-Wisniewski S, Kapur S,Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, and others. Quetiapine: an effective antipsychotic in firstepisode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002;63(11):992-7.
60. Grcevich S, Delong VY. A retrospective analysis of quetiapine in the treatment of psychosis in children and adolescents. Paper presented at the 2001 International Congress on Schizophrenia Research; 2001; Whistler (BC).
61. Good KP, Kiss I, Buiteman C, Woodley H, Rui Q, Whitehorn D, Kopala L. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry 2002;43(Suppl):S45-S49.
62. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol. 2000;15:121-31.
63. Kasper S, Rak IC. Maintenance of Long-term Efficacy and Safety of quetiapine in schizophrenia. Poster presented at a meeting of the American Psychiatric Association; May 2001; New Orleans (LA).
64. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) Study. Clin Ther 2001;23:1839-54.
65. Sajatovic M, Brescan DW, Perez DE, DiGiovanni SK, Hattab H, Ray JB, Bingham CR. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 2001;62:728-32.
66. Ghaemi SN, Katzow JJ. The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatry 1999;11:137-40.
67. Zarate CA Jr, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000;61:185-9.
68. Dunayevich E, Strakowski SM. Quetiapine for treatment-resistant mania. Am J Psychiatry 2000;157:1341.
69. Ghaemi SN, Goldberg JF, Ko JY, McNally EE. Quetiapine treatment of rapid-cycling bipolar disorder: an open prospective. Poster presented at the International Conference on Bipolar Disorder; 2001; Pittsburgh (PA).
70. Brown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in patients with bipolar disorder and cocaine dependence. Poster presented at the International Conference on Bipolar Disorder; 2001; Pittsburgh (PA).
71. Delbello MP, Schweirs ML, Rosenberg HL, Strakowski SM. Quetiapine as adjunctive treatment for adolescent mania. Poster presented at the International Conference on Bipolar Disorder; 2001; Pittsburgh (PA).
72. Schaller JL, Behar D. Quetiapine for refractory mania in a child. J Am Acad Child Adolesc Psychiatry 1999;38:498-9.
73. Sachs G, Mullen JA, Devine NA. Quetiapine versus placebo as adjunct to mood stabilizer for the treatment of acute mania. Poster presented at the 3rd Stanley Foundation Conference for Bipolar Disorders; 2002; Freiburg (Germany).
74. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000;22:1068-84.
75. Juncos J, Evatt ML, Jewart RD. Seroquel (quetiapine) improves psychotic symptoms associated with Parkinson's disease. Poster presented at the American Psychiatric Association Annual Meeting; 1999; Washington (DC).
76. Parsa MA, Greenway H, Bastani B. Quetiapine in the treatment of psychosis in patients with Parkinson's disease and dementia (Lewy body disease variant). Poster presented at the 13th Annual Meeting of the American Association for Geriatric Psychiatry; 12-15 March 2000; Miami (FL).
77. Goldstein JM, Chengappa KR, Parepally H, Brar JS, Mullen J, Schilling A. A random-assignment, double-blind, clinical trial of once- versus twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder. Poster presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology; 9-13 December 2001; Waikoloa (HI).
78. Kasper S, Tauscher J, Heiden A. Quetiapine: efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol 2001;11 (Suppl 4):S405-S413.
79. Kasper S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000;1:783-801.
80. Brecher M, Rak IW, Melvin K, Jones AM. The long-term effect of quetiapine (Seroquel TM) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000;4:287-91.
81. Jeste DV, Glazer WM, Morgenstern H, Pultz JA, Yeung PP. Low incidence of persistent tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly. Poster presented at the 13th Annual Meeting of the of the American Association for Geriatric Psychiatry;12-15 March 2000; Miami (FL).
82. Cutler AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin Ther 2002;24(2):209-22.
83. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26:137-49.
84. Hellewell JS, Kalali AH, Langham SJ, and others. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psych Clin Pract 1999;3:97-105.
85. Smith MA, McCoy R, Hamer J, Brecher M. Optimal titration for quetiapine: pilot trial. Paper presented at the American Psychological Nurses Association; October 6,2002; Dallas (TX).